1
Home
Companies

Dyne Therapeutics

Dyne Therapeutics
Leadership team

Mr. Joshua T. Brumm (CEO, Pres & Director)

Ms. Susanna Gatti High M.B.A. (Chief Operating Officer)

Dr. Oxana Beskrovnaya Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2018
Company Registration
SEC CIK number: 0001818794
Traded as
NASDAQ:DYN
Social Media
URL
https://www.dyne-tx.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
History

Dyne Therapeutics was founded in 2017 by Flagship Pioneering and leverage’s the team’s platform for developing transformative biologic therapies for patients with monogenic muscle diseases. In December 2020, Dyne closed a $200 million Series E financing from leading biotechnology investors.

Mission
Our mission is to develop novel gene therapies for monogenic muscle diseases, to improve the lives of our patients and families.
Vision
We envision a world where our innovative gene therapies deliver an unprecedented level of care to patients with monogenic muscle diseases.
Key Team

Dr. Romesh Subramanian Ph.D. (Co-Founder & Advisor)

Ms. Amy Reilly (Sr. VP and Head of Corp. Communications & Investor Relations)

Mr. Gene Kim (VP of Fin.)

Mr. Richard William Scalzo M.B.A. (Sr. VP, Head of Fin. & Admin. and Treasurer)

Ms. Kate Mitchell (VP & Head of HR)

Dr. Thomas-Christian Mix M.D., M.S. (Sr. VP of Pharmacovigilance)

Ms. Debra Feldman (Sr. VP & Head of Regulatory Affairs)

Recognition and Awards
Dyne Therapeutics has won accolades for its gene therapy platform, development program and financial performance. Examples include the MassBio Edith Previdi Award and the Bank of America Merril Lynch 2020 Biotech Growth Award.
References

https://in.investing.com/equities/dyne-therapeutics-inc

https://finance.yahoo.com/quote/DYN/profile?p=DYN

https://www.crunchbase.com/organization/dyne-therapeutics

https://www.dyne-tx.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Dyne Therapeutics
Leadership team

Mr. Joshua T. Brumm (CEO, Pres & Director)

Ms. Susanna Gatti High M.B.A. (Chief Operating Officer)

Dr. Oxana Beskrovnaya Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2018
Company Registration
SEC CIK number: 0001818794
Traded as
NASDAQ:DYN
Social Media
URL
https://www.dyne-tx.com